Alector reports on recent progress and outlines strategic priorities for 2025

Continue to advance preclinical and research pipeline, including key programs selectively combined with alector brain carrier, enhancing the company's commitment to developing genetically-validated therapies for neurodegeneration

ALEC Ratings Summary

ALEC Quant Ranking